Publications by authors named "Thomas B Karasic"

Claim this Profile
E
Evaluating the Safety and Efficacy of Adding Liver-Directed Radiation Therapy to Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma: A Single-Center Retrospective Cohort Analysis.
Timothy J Brown, Uri Amit, Rohi Gheewala, Edgar Ben-Josef, Thomas B Karasic

Am J Clin Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 dual-dose escalation study of radiation and nab-paclitaxel in patients with unresectable and borderline resectable pancreatic cancer.
Uri Amit, James M Metz, John P Plastaras, Rohi Gheewala, Ursina Teitelbaum, Thomas B Karasic

Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer.
Lipika Goyal, Funda Meric-Bernstam, Antoine Hollebecque, Juan W Valle, Chigusa Morizane, Thomas B Karasic

Future Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Classification and Regression Trees to Predict for Survival for Patients With Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab.
Timothy J Brown, Phyllis A Gimotty, Ronac Mamtani, Thomas B Karasic, Yu-Xiao Yang

JCO Clin Cancer Inform· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes and risk stratification in unresectable biliary tract cancers undergoing radiation therapy.
Uri Amit, Misra Shagun, John P Plastaras, James M Metz, Thomas B Karasic

Radiat Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.
Mark Yarchoan, John D Powderly, Bruno R Bastos, Thomas B Karasic, Oxana V Crysler

Cancer Res Commun· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Carbon Monoxide Enhances Autophagy Modulation in Prostate, Pancreatic, and Lung Cancers.
Jianling Bi, Emily Witt, Megan K McGovern, Arielle B Cafi, Lauren L Rosenstock, Thomas B Karasic

Adv Sci (Weinh)· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib.
Timothy J Brown, Arielle Yablonovitch, Jacob E Till, Jennifer Yen, Lesli A Kiedrowski, Thomas B Karasic

Clin Cancer Res· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis.
Timothy J Brown, Ronac Mamtani, Phyllis A Gimotty, Thomas B Karasic, Yu-Xiao Yang

J Cancer Res Clin Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Precision Medicine and Immunotherapy Have Arrived for Cholangiocarcinoma: An Overview of Recent Approvals and Ongoing Clinical Trials.
Thomas B Karasic, Jennifer R Eads, Lipika Goyal

JCO Precis Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of nivolumab and sorafenib for first systemic therapy in patients with hepatocellular carcinoma and Child-Pugh B cirrhosis.
William J Chapin, Wei-Ting Hwang, Thomas B Karasic, Anne Marie McCarthy, David E Kaplan

Cancer Med· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Futibatinib for -Rearranged Intrahepatic Cholangiocarcinoma.
Lipika Goyal, Funda Meric-Bernstam, Antoine Hollebecque, Juan W Valle, Chigusa Morizane, Thomas B Karasic

N Engl J Med· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer.
Thomas B Karasic, Timothy J Brown, Charles Schneider, Ursina R Teitelbaum, Kim A Reiss

Oncologist· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DWI Metrics Differentiating Benign Intraductal Papillary Mucinous Neoplasms from Invasive Pancreatic Cancer: A Study in GEM Models.
Miguel Romanello Joaquim, Emma E Furth, Yong Fan, Hee Kwon Song, Stephen Pickup, Thomas B Karasic

Cancers (Basel)· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multianalyte Prognostic Signature Including Circulating Tumor DNA and Circulating Tumor Cells in Patients With Advanced Pancreatic Adenocarcinoma.
William J Chapin, Jacob E Till, Wei-Ting Hwang, Jennifer R Eads, Thomas B Karasic

JCO Precis Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends of Clinical Outcomes of Patients with Advanced Hepatocellular Carcinoma Treated with First-Line Sorafenib in Randomized Controlled Trials.
Timothy J Brown, Arjun Gupta, Ramy Sedhom, Muhammad S Beg, Thomas B Karasic

Gastrointest Tumors· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in , , or .
Kim A Reiss, Rosemarie Mick, Mark H O'Hara, Ursina Teitelbaum, Thomas B Karasic

J Clin Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Pilot Study of Galunisertib plus Stereotactic Body Radiotherapy in Patients with Advanced Hepatocellular Carcinoma.
Kim A Reiss, Max M Wattenberg, Nevena Damjanov, Elizabeth Prechtel Dunphy, Mona Jacobs-Small, Thomas B Karasic

Mol Cancer Ther· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy and safety of definitive concurrent chemoradiotherapy for non-operable esophageal cancer.
Alexandra D Dreyfuss, Andrew R Barsky, E Paul Wileyto, Jennifer R Eads, John C Kucharczuk, Thomas B Karasic

Cancer Med· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Trial of Palbociclib in Patients with Advanced Esophageal or Gastric Cancer.
Thomas Benjamin Karasic, Mark H O'Hara, Ursina R Teitelbaum, Nevena Damjanov, Bruce J Giantonio

Oncologist· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Study of GGTI-2418 (Geranylgeranyl Transferase I Inhibitor) in Patients with Advanced Solid Tumors.
Thomas B Karasic, E Gabriela Chiorean, Said M Sebti, Peter J O'Dwyer

Target Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial.
Thomas B Karasic, Mark H O'Hara, Arturo Loaiza-Bonilla, Kim A Reiss, Ursina R Teitelbaum

JAMA Oncol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective?
Thomas B Karasic, Mark A Rosen, Peter J O'Dwyer

Cancer Chemother Pharmacol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development.
Amy S Clark, Thomas B Karasic, Angela DeMichele, David J Vaughn, Mark O'Hara

JAMA Oncol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disruption of IGF-1R signaling increases TRAIL-induced apoptosis: a new potential therapy for the treatment of melanoma.
Thomas B Karasic, Tom K Hei, Vladimir N Ivanov

Exp Cell Res· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis